CN115010665A - Method for synthesizing terbutaline sulfate impurity B - Google Patents
Method for synthesizing terbutaline sulfate impurity B Download PDFInfo
- Publication number
- CN115010665A CN115010665A CN202210935533.3A CN202210935533A CN115010665A CN 115010665 A CN115010665 A CN 115010665A CN 202210935533 A CN202210935533 A CN 202210935533A CN 115010665 A CN115010665 A CN 115010665A
- Authority
- CN
- China
- Prior art keywords
- compound
- terbutaline sulfate
- impurity
- reaction
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 title claims abstract description 38
- 229960005105 terbutaline sulfate Drugs 0.000 title claims abstract description 32
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 9
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 6
- 238000005886 esterification reaction Methods 0.000 claims abstract description 6
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 4
- 238000006722 reduction reaction Methods 0.000 claims abstract description 4
- 238000006467 substitution reaction Methods 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 229940125904 compound 1 Drugs 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- 229940125782 compound 2 Drugs 0.000 claims description 10
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000010189 synthetic method Methods 0.000 claims description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- WUXKAYZEXYAYIT-UHFFFAOYSA-N 2-bromo-1-(3,5-dihydroxyphenyl)ethanone Chemical compound OC1=CC(O)=CC(C(=O)CBr)=C1 WUXKAYZEXYAYIT-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 6
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- 239000008098 formaldehyde solution Substances 0.000 claims description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 229960000195 terbutaline Drugs 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 claims description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 31
- 239000002994 raw material Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 2
- 238000010812 external standard method Methods 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 239000003208 petroleum Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- REJPDMLLCDXIOV-UHFFFAOYSA-N but-2-ynal Chemical compound CC#CC=O REJPDMLLCDXIOV-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于药物化学技术领域,具体涉及一种硫酸特布他林杂质B的合成方法。以对2‑溴‑3',5'‑二羟基苯乙酮为原料,经过酯化反应、取代反应、环合反应、水解反应、还原反应5步反应制得硫酸特布他林杂质B。本发明所述的合成方法,反应过程简单,原料易得,总收率大于50%,对采用外标法来严格控制硫酸特布他林杂质B含量做出贡献;其反应条件温和,产物纯度高,适用于药品质量研究,为提高硫酸特布他林原料药的质量提供保证。
The invention belongs to the technical field of medicinal chemistry, and in particular relates to a method for synthesizing impurity B of terbutaline sulfate. Using p-2-bromo-3', 5'-dihydroxyacetophenone as a raw material, terbutaline sulfate impurity B is prepared through 5 steps of esterification reaction, substitution reaction, cyclization reaction, hydrolysis reaction and reduction reaction. The synthesis method of the invention has the advantages of simple reaction process, readily available raw materials, and a total yield of more than 50%, which contributes to strictly controlling the content of impurity B of terbutaline sulfate by using an external standard method; the reaction conditions are mild, and the product purity is High, suitable for drug quality research, to provide assurance for improving the quality of terbutaline sulfate APIs.
Description
技术领域technical field
本发明属于药物化学技术领域,具体涉及一种硫酸特布他林杂质B的合成方法。The invention belongs to the technical field of medicinal chemistry, and in particular relates to a method for synthesizing impurity B of terbutaline sulfate.
背景技术Background technique
硫酸特布他林(terbutaline,TBT),又名间羟舒喘灵、叔丁喘宁、特布他林硫酸盐,是一种选择性β2肾上腺素受体兴奋剂,既有平喘、祛痰作用,又有舒张支气管作用,临床可用于支气管哮喘、慢性支气管炎、肺气肿和其他肺部疾病所引起的支气管痉挛,也可用于预防早产及胎儿窒息。其结构式如下:Terbutaline sulfate (terbutaline, TBT), also known as metahydroxysalbutamol, terbutaline, terbutaline sulfate, is a selective beta 2 adrenergic receptor stimulant, both antiasthmatic, It has expectorant effect and bronchial relaxation effect. It can be used clinically for bronchospasm caused by bronchial asthma, chronic bronchitis, emphysema and other lung diseases. It can also be used to prevent premature birth and fetal asphyxia. Its structural formula is as follows:
硫酸特布他林的欧洲药典标准报道了4个杂质,其中杂质B结构如下:The European Pharmacopoeia standard of terbutaline sulfate reports 4 impurities, wherein the impurity B structure is as follows:
为保证临床用药安全,需要对硫酸特布他林中的杂质B进行质量控制。由于硫酸特布他林制备过程中只有微量杂质B产生,不易分离纯化作为杂质对照品,且现阶段无文献报道该杂质的合成路线,因此研究一种硫酸特布他林杂质B的方法非常有必要。In order to ensure the safety of clinical medication, the quality control of impurity B in terbutaline sulfate is required. Since only a trace amount of impurity B is produced in the preparation process of terbutaline sulfate, it is not easy to separate and purify as an impurity reference substance, and there is no literature report on the synthetic route of this impurity at this stage. Therefore, it is very useful to study a method of terbutaline sulfate impurity B. necessary.
发明内容SUMMARY OF THE INVENTION
针对现阶段对硫酸特布他林中的杂质B进行质量控制存在的问题,本发明提供一种硫酸特布他林杂质B的合成方法,以对2-溴-3', 5'-二羟基苯乙酮为原料,经过酯化反应、取代反应、环合反应、水解反应、还原反应5步反应制得;原料易得,反应条件温和,总收率高,产物纯度高,为提高硫酸特布他林原料药的质量提供保证。Aiming at the problem that the impurity B in terbutaline sulfate is carried out quality control at the present stage, the invention provides a kind of synthetic method of terbutaline sulfate impurity B, to 2-bromo-3', 5'-dihydroxyl Acetophenone is used as a raw material, and is obtained through 5 steps of esterification reaction, substitution reaction, cyclization reaction, hydrolysis reaction and reduction reaction; the raw materials are easily available, the reaction conditions are mild, the total yield is high, and the product purity is high. Guarantee the quality of butaline APIs.
本发明的技术方案如下:The technical scheme of the present invention is as follows:
一种硫酸特布他林杂质B的合成方法,包括以下步骤:A synthetic method of terbutaline sulfate impurity B, comprising the following steps:
(1)2-溴-3', 5'-二羟基苯乙酮与乙酸酐在碱作用下,经酯化反应制得化合物1;(1)
(2)化合物1溶于溶剂1中,与叔丁胺经取代反应制得化合物2;(2)
(3)化合物2溶于溶剂2中,经环合反应制得化合物3;(3) Compound 2 is dissolved in solvent 2, and
(4)化合物3溶于溶剂3中,加入碱性溶液,经水解反应制得化合物4;(4)
(5)化合物4于溶剂4中,经还原反应制得杂质B;(5)
其中,上述化合物1-4及杂质B的结构式如下所示:Wherein, the structural formula of above-mentioned compound 1-4 and impurity B is as follows:
。 .
进一步地,步骤(1)中还包括溶剂4,将2-溴-3', 5'-二羟基苯乙酮溶解后,加入乙酸酐,在碱作用下进行酯化反应;所述的溶剂4为二氯甲烷、甲苯、二氧六环、乙腈、四氢呋喃、DMF、DMSO中的一种或几种以任意比例的混合液。Further, step (1) also includes
优选地,步骤(1)中所述的碱为碳酸钾、碳酸钠、氢氧化钠、氢氧化钾、三乙胺或二异丙基乙胺中的一种,优选三乙胺。Preferably, the base described in step (1) is one of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, triethylamine or diisopropylethylamine, preferably triethylamine.
优选地,所述的溶剂1为甲醇、乙醇、甲苯、二氧六环、乙腈、四氢呋喃、DMF或DMSO中的一种或几种以任意比例的混合液,优选甲醇或乙醇。Preferably, the
优选地,所述的叔丁胺与化合物1的摩尔比为1~4:1。Preferably, the molar ratio of the tert-butylamine to
优选地,所述的溶剂2为水、甲醇、乙醇、甲苯、二氧六环、乙腈、四氢呋喃、DMF或DMSO中的一种或几种以任意比例的混合液,优选甲醇或乙醇与水的混合溶液。Preferably, the solvent 2 is a mixed solution of one or more of water, methanol, ethanol, toluene, dioxane, acetonitrile, tetrahydrofuran, DMF or DMSO in any proportion, preferably methanol or ethanol and water mixture.
优选地,步骤(3)中,所述环合反应所使用的试剂为甲醛水溶液或多聚甲醛,优选多聚甲醛。Preferably, in step (3), the reagent used in the cyclization reaction is an aqueous formaldehyde solution or paraformaldehyde, preferably paraformaldehyde.
优选地,步骤(4)中,所述的溶剂3为甲醇、乙醇、异丙醇、四氢呋喃或二氧六环中的一种与水的混合溶液,优选甲醇;所述的碱性溶液为氢氧化钠、氢氧化钾或氢氧化锂溶液中的一种,优选氢氧化钠溶液。Preferably, in step (4), the
优选地,步骤(5)中,所述的溶剂4为甲醇、乙醇、异丙醇、四氢呋喃、二氧六环、二氯甲烷或1, 2-二氯乙烷中的一种或几种以任意比例的混合液,优选甲醇。Preferably, in step (5), the
优选地,步骤(5)中,所述的还原剂为硼氢化钠、四氢铝锂。Preferably, in step (5), the reducing agent is sodium borohydride and lithium aluminum tetrahydrogen.
合成的工艺流程为:The synthetic process is as follows:
与现有技术相比,本发明的有益效果如下:Compared with the prior art, the beneficial effects of the present invention are as follows:
1、本发明所述的硫酸特布他林杂质B的合成方法,共5步反应,原料易得,总收率大于50%,对采用外标法来严格控制硫酸特布他林杂质B含量做出贡献。1, the synthetic method of the terbutaline sulfate impurity B of the present invention, a total of 5 steps are reacted, the raw materials are easy to obtain, and the total yield is greater than 50%, and the external standard method is used to strictly control the terbutaline sulfate impurity B content. make a contribution.
2、本发明合成方法操作简单,反应条件温和,产物纯度高,适用于药品质量研究,为提高硫酸特布他林原料药的质量提供保证。2. The synthesis method of the present invention has simple operation, mild reaction conditions and high product purity, is suitable for drug quality research, and provides guarantee for improving the quality of terbutaline sulfate crude drug.
附图说明Description of drawings
图1是本发明实施例3制备的硫酸特布他林杂质B的核磁图谱;Fig. 1 is the nuclear magnetic spectrum of the terbutaline sulfate impurity B prepared by the embodiment of the
图2是本发明实施例3制备的硫酸特布他林杂质B的质谱;Fig. 2 is the mass spectrum of the terbutaline sulfate impurity B prepared by the embodiment of the
图3是本发明实施例3制备的硫酸特布他林杂质B的液相纯度图谱。Fig. 3 is the liquid phase purity spectrum of terbutaline sulfate impurity B prepared in Example 3 of the present invention.
具体实施方式Detailed ways
下面结合实施例对本发明做进一步说明,但不限定本发明。The present invention will be further described below in conjunction with the examples, but the present invention is not limited.
实施例中用到的所有原料除特殊说明外,均为市购。All raw materials used in the examples are commercially available unless otherwise specified.
实施例1Example 1
1. 化合物1的合成1. Synthesis of
将2-溴-3', 5'-二羟基苯乙酮(0.46g,2.0mmol))溶于4ml二氯甲烷中,加入1ml乙酸酐、二异丙基乙胺(1.3g,10.0mmol),室温搅拌反应,TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸干,加入20ml水,并用20mlx3乙酸乙酯萃取,合并有机层。饱和碳酸氢钠溶液洗涤,纯水洗涤,无水硫酸钠干燥后蒸干溶剂,减压浓缩后柱层析分离纯化,得白色固体0.52g,即化合物1,收率83%。2-Bromo-3',5'-dihydroxyacetophenone (0.46g, 2.0mmol)) was dissolved in 4ml of dichloromethane, and 1ml of acetic anhydride and diisopropylethylamine (1.3g, 10.0mmol) were added. , the reaction was stirred at room temperature, and the reaction was monitored by TLC (petroleum ether:ethyl acetate=2:1, V/V). Evaporate to dryness under reduced pressure, add 20 ml of water, extract with 20 ml×3 ethyl acetate, and combine the organic layers. Washed with saturated sodium bicarbonate solution, washed with pure water, dried over anhydrous sodium sulfate, evaporated to dryness, concentrated under reduced pressure, separated and purified by column chromatography to obtain 0.52 g of white solid, namely
2. 化合物2的合成2. Synthesis of Compound 2
将化合物1(0.52g,1.65mmol)溶于10ml甲醇中,并加入叔丁胺(0.48g,6.6mmol),升温至60~70℃,搅拌6小时,TLC检测反应完毕(石油醚:乙酸乙酯=2:1,V/V),减压蒸馏,所得剩余物经柱层析分离提纯,得白色固体0.48g,即为化合物2,收率95%。Compound 1 (0.52 g, 1.65 mmol) was dissolved in 10 ml of methanol, tert-butylamine (0.48 g, 6.6 mmol) was added, the temperature was raised to 60-70 ° C, and stirred for 6 hours. TLC detected the completion of the reaction (petroleum ether: ethyl acetate = 2:1, V/V), distilled under reduced pressure, and the obtained residue was separated and purified by column chromatography to obtain 0.48 g of white solid, which was compound 2, and the yield was 95%.
3. 化合物3的合成3. Synthesis of
将化合物2(0.48g,1.56mmol)溶于5ml水和5ml乙醇混合溶剂中,并加入1ml甲醛水溶液,室温下搅拌反应72h。TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸出乙醇,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体0.42g,即化合物3,收率84%。Compound 2 (0.48 g, 1.56 mmol) was dissolved in a mixed solvent of 5 ml of water and 5 ml of ethanol, and 1 ml of aqueous formaldehyde solution was added, and the reaction was stirred at room temperature for 72 h. The completion of the reaction was monitored by TLC (petroleum ether:ethyl acetate=2:1, V/V). The ethanol was evaporated under reduced pressure, cooled to 0~5°C, stirred and crystallized for 1 h, filtered, and dried to constant weight to obtain 0.42 g of a white solid, namely
4. 化合物4的合成4. Synthesis of
将化合物3(0.42g,1.32mmol)溶于10mL乙醇中,搅拌加入氢氧化钠(0.4g,10.0mmol)和纯化水(2mL),升温至50±2℃,搅拌2小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),用2M盐酸溶液调节反应体系pH至5-6,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体0.27g,即化合物4,收率87%。Compound 3 (0.42 g, 1.32 mmol) was dissolved in 10 mL of ethanol, sodium hydroxide (0.4 g, 10.0 mmol) and purified water (2 mL) were added with stirring, the temperature was raised to 50±2 °C, stirred for 2 hours, TLC detected the completion of the reaction (Petroleum ether:ethyl acetate=1:1, V/V), adjust the pH of the reaction system to 5-6 with 2M hydrochloric acid solution, cool down to 0~5 °C, stir for crystallization for 1 h, filter, and dry to constant weight to obtain a white solid 0.27g, namely
5. 杂质B的合成5. Synthesis of Impurity B
将化合物4(0.27g,1.15mmol)溶于5mL四氢呋喃中,搅拌降温至0~5℃,加入四氢铝锂(0.17g,4.6mmol),搅拌4小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),向反应液中缓慢滴加饱和氯化铵纯化水(15mL)中,加入乙酸乙酯(15mL),搅拌5分钟,静置分层,保留乙酸乙酯相,无水硫酸钠干燥,减压浓缩后柱层析分离,得类白色固体0.24g,即杂质B,收率88%,五步总收率50.5%。Compound 4 (0.27 g, 1.15 mmol) was dissolved in 5 mL of tetrahydrofuran, stirred and cooled to 0~5 °C, added with lithium tetrahydroaluminum (0.17 g, 4.6 mmol), stirred for 4 hours, TLC detected the completion of the reaction (petroleum ether: acetic acid) ethyl ester=1:1, V/V), slowly add saturated ammonium chloride purified water (15 mL) dropwise to the reaction solution, add ethyl acetate (15 mL), stir for 5 minutes, stand for stratification, keep ethyl acetate The ester phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain 0.24 g of an off-white solid, namely impurity B, with a yield of 88% and a five-step total yield of 50.5%.
实施例2Example 2
1. 化合物1的合成1. Synthesis of
将2-溴-3', 5'-二羟基苯乙酮(0.46g,2.0mmol))溶于4ml乙腈中,加入1ml乙酸酐、碳酸钠(1.06g,10.0mmol),室温搅拌反应,TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸干,加入20ml水,并用20mlx3乙酸乙酯萃取,合并有机层。饱和碳酸氢钠溶液洗涤,纯水洗涤,无水硫酸钠干燥后蒸干溶剂,减压浓缩后柱层析分离纯化,得白色固体0.52g,即化合物1,收率83%。2-Bromo-3', 5'-dihydroxyacetophenone (0.46g, 2.0mmol)) was dissolved in 4ml acetonitrile, 1ml acetic anhydride and sodium carbonate (1.06g, 10.0mmol) were added, and the reaction was stirred at room temperature. TLC The completion of the reaction was monitored (petroleum ether:ethyl acetate=2:1, V/V). Evaporate to dryness under reduced pressure, add 20 ml of water, extract with 20 ml×3 ethyl acetate, and combine the organic layers. Washed with saturated sodium bicarbonate solution, washed with pure water, dried over anhydrous sodium sulfate, evaporated to dryness, concentrated under reduced pressure, and purified by column chromatography to obtain 0.52 g of white solid, namely
2. 化合物2的合成2. Synthesis of Compound 2
将化合物1(0.52g,1.65mmol)溶于10ml四氢呋喃中,并加入叔丁胺(0.48g,1.65mmol),升温至60~70℃,搅拌6小时,TLC检测反应完毕(石油醚:乙酸乙酯=2:1,V/V),减压蒸馏,所得剩余物经柱层析分离提纯,得白色固体0.47g,即为化合物2,收率91%。Compound 1 (0.52 g, 1.65 mmol) was dissolved in 10 ml of tetrahydrofuran, and tert-butylamine (0.48 g, 1.65 mmol) was added, the temperature was raised to 60-70 ° C, and stirred for 6 hours. TLC detected the completion of the reaction (petroleum ether: ethyl acetate = 2:1, V/V), distilled under reduced pressure, and the obtained residue was separated and purified by column chromatography to obtain 0.47 g of white solid, which was compound 2, with a yield of 91%.
3. 化合物3的合成3. Synthesis of
将化合物2(0.47g,1.50mmol)溶于5ml水和5ml乙醇混合溶剂中,并加入1ml甲醛水溶液,室温下搅拌反应72h。TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸出乙醇,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体0.42g,即化合物3,收率88%。Compound 2 (0.47 g, 1.50 mmol) was dissolved in a mixed solvent of 5 ml of water and 5 ml of ethanol, 1 ml of aqueous formaldehyde solution was added, and the reaction was stirred at room temperature for 72 h. The completion of the reaction was monitored by TLC (petroleum ether:ethyl acetate=2:1, V/V). The ethanol was evaporated under reduced pressure, cooled to 0~5°C, stirred and crystallized for 1 h, filtered, and dried to constant weight to obtain 0.42 g of a white solid, namely
4. 化合物4的合成4. Synthesis of
将化合物3(0.42g,1.32mmol)溶于10mL乙醇中,搅拌加入氢氧化锂(0.24g,10.0mmol)和纯化水(2mL),升温至50±2℃,搅拌2小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),用2M盐酸溶液调节反应体系pH至5-6,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体0.26g,即化合物4,收率87%。Compound 3 (0.42 g, 1.32 mmol) was dissolved in 10 mL of ethanol, lithium hydroxide (0.24 g, 10.0 mmol) and purified water (2 mL) were added with stirring, the temperature was raised to 50±2 °C, stirred for 2 hours, TLC detected the completion of the reaction (Petroleum ether:ethyl acetate=1:1, V/V), adjust the pH of the reaction system to 5-6 with 2M hydrochloric acid solution, cool down to 0~5 °C, stir for crystallization for 1 h, filter, and dry to constant weight to obtain a white solid 0.26g, namely
5. 杂质B的合成5. Synthesis of Impurity B
将化合物4(0.26g,1.11mmol)溶于5mL二氧六环中,搅拌降温至0~5℃,加入四氢铝锂(0.17g,4.6mmol),搅拌4小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),向反应液中缓慢滴加饱和氯化铵纯化水(15mL)中,加入乙酸乙酯(15mL),搅拌5分钟,静置分层,保留乙酸乙酯相,无水硫酸钠干燥,减压浓缩后柱层析分离,得类白色固体0.25g,即杂质B,收率95%,五步总收率52.7%。Compound 4 (0.26g, 1.11mmol) was dissolved in 5mL of dioxane, stirred and cooled to 0~5°C, added with lithium tetrahydroaluminum (0.17g, 4.6mmol), stirred for 4 hours, TLC detected the completion of the reaction (petroleum ether: ethyl acetate=1:1, V/V), slowly dropwise added saturated ammonium chloride purified water (15 mL) to the reaction solution, added ethyl acetate (15 mL), stirred for 5 minutes, allowed to stand for layers, The ethyl acetate phase was retained, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain 0.25 g of an off-white solid, namely impurity B, with a yield of 95% and a five-step total yield of 52.7%.
实施例3Example 3
1. 化合物1的合成1. Synthesis of
将2-溴-3', 5'-二羟基苯乙酮(4.62g,0.02mol))溶于40ml乙酸酐中,加入三乙胺(3.03g,0.03mol)催化,室温搅拌反应,TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸干,加入200ml水,并用50mlx3乙酸乙酯萃取,合并有机层。饱和碳酸氢钠溶液洗涤,纯水洗涤,无水硫酸钠干燥后蒸干溶剂,减压浓缩后柱层析分离纯化,得白色固体5.50g,即化合物1,收率87%。2-Bromo-3', 5'-dihydroxyacetophenone (4.62g, 0.02mol)) was dissolved in 40ml of acetic anhydride, triethylamine (3.03g, 0.03mol) was added for catalysis, the reaction was stirred at room temperature and monitored by TLC The reaction was completed (petroleum ether:ethyl acetate=2:1, V/V). Evaporate to dryness under reduced pressure, add 200 ml of water, extract with 50 ml×3 ethyl acetate, and combine the organic layers. Washed with saturated sodium bicarbonate solution, washed with pure water, dried over anhydrous sodium sulfate, evaporated to dryness, concentrated under reduced pressure, separated and purified by column chromatography to obtain 5.50 g of white solid, namely
2. 化合物2的合成2. Synthesis of Compound 2
将化合物1(5.50g,0.0175mol)溶于50ml乙醇中,并加入叔丁胺(5.12g,0.070mol),升温至60~70℃,搅拌6小时,TLC检测反应完毕(石油醚:乙酸乙酯=2:1,V/V),减压蒸馏,所得剩余物经柱层析分离提纯,得白色固体5.12g,即为化合物2,收率95%。Compound 1 (5.50 g, 0.0175 mol) was dissolved in 50 ml of ethanol, tert-butylamine (5.12 g, 0.070 mol) was added, the temperature was raised to 60-70 ° C, and stirred for 6 hours. TLC detected the completion of the reaction (petroleum ether: ethyl acetate = 2:1, V/V), distilled under reduced pressure, and the obtained residue was separated and purified by column chromatography to obtain 5.12 g of white solid, which was compound 2, and the yield was 95%.
3. 化合物3的合成3. Synthesis of
将化合物2(5.12g,0.0167mol)溶于20ml水和20ml甲醇混合溶剂中,并加入多聚甲醛(4.51g,0.0501mol),室温下搅拌反应72h。TLC监控反应结束(石油醚:乙酸乙酯=2:1,V/V)。减压蒸出甲醇,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体4.72g,即化合物3,收率88%。Compound 2 (5.12 g, 0.0167 mol) was dissolved in a mixed solvent of 20 ml of water and 20 ml of methanol, and paraformaldehyde (4.51 g, 0.0501 mol) was added, and the reaction was stirred at room temperature for 72 h. The completion of the reaction was monitored by TLC (petroleum ether:ethyl acetate=2:1, V/V). The methanol was evaporated under reduced pressure, cooled to 0~5°C, stirred for crystallization for 1 h, filtered, and dried to constant weight to obtain 4.72 g of a white solid, namely
4. 化合物4的合成4. Synthesis of
将化合物3(4.72g,0.0148mol)溶于40mL乙醇中,搅拌加入氢氧化钠(2.96g,0.074mmol)和纯化水(10mL),升温至50±2℃,搅拌2小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),用2M盐酸溶液调节反应体系pH至5-6,降温至0~5℃搅拌析晶1h,过滤,干燥至恒重得白色固体3.05g,即化合物4,收率88%。Compound 3 (4.72 g, 0.0148 mol) was dissolved in 40 mL of ethanol, sodium hydroxide (2.96 g, 0.074 mmol) and purified water (10 mL) were added with stirring, the temperature was raised to 50±2 °C, stirred for 2 hours, TLC detected the completion of the reaction (Petroleum ether:ethyl acetate=1:1, V/V), adjust the pH of the reaction system to 5-6 with 2M hydrochloric acid solution, cool down to 0~5 °C, stir for crystallization for 1 h, filter, and dry to constant weight to obtain a white solid 3.05g, namely
5. 杂质B的合成5. Synthesis of Impurity B
将化合物4(3.05g,0.0130mol)溶于40mL甲醇中,搅拌降温至0~5℃,分批加入硼氢化钠(0.98g,0.026mmol),搅拌4小时,TLC检测反应完毕(石油醚:乙酸乙酯=1:1,V/V),将反应液倒入纯化水(100mL)中,加入乙酸乙酯(100mL),搅拌5分钟,静置分层,保留乙酸乙酯相,无水硫酸钠干燥,减压浓缩后柱层析分离,得类白色固体2.77g,即杂质B,收率90%,五步总收率58.4%。Compound 4 (3.05 g, 0.0130 mol) was dissolved in 40 mL of methanol, stirred and cooled to 0~5 °C, sodium borohydride (0.98 g, 0.026 mmol) was added in batches, stirred for 4 hours, TLC detected the completion of the reaction (petroleum ether: ethyl acetate = 1:1, V/V), pour the reaction solution into purified water (100 mL), add ethyl acetate (100 mL), stir for 5 minutes, stand for stratification, keep the ethyl acetate phase, anhydrous It was dried over sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain 2.77 g of off-white solid, namely impurity B, with a yield of 90% and a five-step total yield of 58.4%.
将制得的硫酸特布他林杂质B进行高分辨质谱、核磁结构数据、液相纯度分析,结果为HR-MS(m/z): 238.1530 [M+H]+1; H1-NMR(DMSO-d 6 , 400MHz) δ: 1.42(s, 6H, 3CH3),3.42(m, 2H, CH2), 4.18(m, 2H, CH2), 4.92(t, 1H, CH), 6.38(s, 1H, Ph), 6.42(s,1H, Ph)。分析结果显示结构正确,纯度为99.52%。The obtained terbutaline sulfate impurity B was subjected to high-resolution mass spectrometry, nuclear magnetic structure data, and liquid phase purity analysis, and the results were HR-MS ( m/z ): 238.1530 [M+H] +1 ; H 1 -NMR ( DMSO- d 6 , 400MHz) δ: 1.42 (s, 6H, 3CH 3 ), 3.42 (m, 2H, CH 2 ), 4.18 (m, 2H, CH 2 ), 4.92 (t, 1H, CH ), 6.38 ( s, 1H, Ph), 6.42 (s, 1H, Ph). The analytical results showed that the structure was correct and the purity was 99.52%.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210935533.3A CN115010665A (en) | 2022-08-05 | 2022-08-05 | Method for synthesizing terbutaline sulfate impurity B |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210935533.3A CN115010665A (en) | 2022-08-05 | 2022-08-05 | Method for synthesizing terbutaline sulfate impurity B |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115010665A true CN115010665A (en) | 2022-09-06 |
Family
ID=83066109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210935533.3A Pending CN115010665A (en) | 2022-08-05 | 2022-08-05 | Method for synthesizing terbutaline sulfate impurity B |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115010665A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104016979A (en) * | 2012-11-23 | 2014-09-03 | 广东东阳光药业有限公司 | Substituted cyclic compound as well as use method and application thereof |
WO2015050212A1 (en) * | 2013-10-02 | 2015-04-09 | 日産化学工業株式会社 | T-type calcium channel blocker |
WO2016065226A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhobitors |
CN107011187A (en) * | 2017-04-17 | 2017-08-04 | 山东科源制药股份有限公司 | A kind of preparation method of isoproterenol sulfate dihydrate |
CN110057932A (en) * | 2019-04-22 | 2019-07-26 | 上海旭东海普药业有限公司 | Method of the efficient liquid phase chromatographic analysis bricalin in relation to substance |
CN111454164A (en) * | 2020-04-27 | 2020-07-28 | 山东美泰医药有限公司 | Preparation method of terbutaline sulfate |
-
2022
- 2022-08-05 CN CN202210935533.3A patent/CN115010665A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104016979A (en) * | 2012-11-23 | 2014-09-03 | 广东东阳光药业有限公司 | Substituted cyclic compound as well as use method and application thereof |
WO2015050212A1 (en) * | 2013-10-02 | 2015-04-09 | 日産化学工業株式会社 | T-type calcium channel blocker |
WO2016065226A1 (en) * | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhobitors |
CN107011187A (en) * | 2017-04-17 | 2017-08-04 | 山东科源制药股份有限公司 | A kind of preparation method of isoproterenol sulfate dihydrate |
CN110057932A (en) * | 2019-04-22 | 2019-07-26 | 上海旭东海普药业有限公司 | Method of the efficient liquid phase chromatographic analysis bricalin in relation to substance |
CN111454164A (en) * | 2020-04-27 | 2020-07-28 | 山东美泰医药有限公司 | Preparation method of terbutaline sulfate |
Non-Patent Citations (6)
Title |
---|
ALPATOVA, T. V.等: "Synthesis and radioprotectant properties of some derivatives of 6-hydroxy-1,2,3,4-tetrahydroisoquinoline", 《KHIMIKO-FARMATSEVTICHESKII ZHURNAL》 * |
BATES, HANS A.等: "Effect of pH on the regioselectivity of Pictet-Spengler reactions of 3-hydroxyphenethylamines with formaldehyde and acetaldehyde", 《JOURNAL OF ORGANIC CHEMISTRY》 * |
M.K. HENZE等: "Screening ofb-2 agonists and confirmation of fenoterol,orciprenaline, reproterol and terbutaline with gas chromatography–mass spectrometry as tetrahydroisoquinoline derivatives", 《JOURNAL OF CHROMATOGRAPHY B》 * |
N. KUCHARCZYK等: "The formaldehyde-donating activity of N5,N1 O-methylene tetrahydrofolic acid in xenobiotic biotransformation", 《XENOBIOTICA》 * |
NA ZHOU等: "Identification of Degradation Products and Process Impurities from Terbutaline Sulfate by UHPLC‑Q‑TOF‑MS/MS and In Silico Toxicity Prediction", 《CHROMATOGRAPHIA》 * |
武钦佩等: "《保护基化学》", 31 January 2007, 化学工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014010263B1 (en) | METHOD OF PREPARATION OF ULIPRISTAL AND INTERMEDIATE ACETATE | |
CN110950765A (en) | A kind of preparation method of terbutaline sulfate | |
CN101863948B (en) | High-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or composition thereof and preparation method thereof | |
CN109206317B (en) | Preparation process of amantadine nitrate derivative | |
WO2011079672A1 (en) | Preparation method for 3-β-arachidylamido-7α,12α,5β-cholan-24-carboxylic acid | |
CN114014773A (en) | Preparation method of N-acetyl-L-aspartic acid | |
CN115010665A (en) | Method for synthesizing terbutaline sulfate impurity B | |
CN116514704B (en) | Rafenacin intermediate and preparation method thereof | |
CN112250586A (en) | Preparation method of terbutaline sulfate and B crystal form thereof | |
CN112174798B (en) | Synthesis method of Sakuba/valsartan sodium LCZ696 | |
CN114195739B (en) | High-purity roxatidine acetate hydrochloride, intermediate thereof and preparation method thereof | |
CN115073313B (en) | Method for synthesizing terbutaline sulfate impurity C | |
EP4452409A1 (en) | Synthesis of cholesterol form bisnoralcohol | |
CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
CN113004245B (en) | Preparation method of desloratadine | |
CN109096098B (en) | A kind of preparation method of trans-1,3-dihydroxycyclobutane-1-carboxylic acid | |
JP2000502102A (en) | Method for preparing 9,11β-epoxide steroid | |
CN111018928A (en) | Synthetic method and application of gastrodin hemihydrate | |
JP2020070296A (en) | Method for producing linagliptin | |
CN116178216B (en) | Method for synthesizing EP impurity P of aminosalicylic acid | |
CN112979723B (en) | Gemcitabine intermediate purification method | |
CN112279759B (en) | Method for synthesizing 2-fluorocyclobutyl methylamine and intermediate thereof | |
CN114315687A (en) | A kind of preparation method of acemetacin impurity D | |
CN119191945A (en) | Synthetic method of (+/-) -guaifenesin-beta-O-4' -dihydroconiferyl alcohol | |
CN109988076A (en) | A kind of levothyroxine sodium impurity and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |